Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stoke TherapeuticsSTOK +0.78%45 3-Year EBITDA Growth Rate is 50.60% as of Jun. 2026. GuruFocus rates STOK with a GF Score™ of 45/100 and a GF Value™ of $9.45 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,135 Biotechnology companies, Stoke Therapeutics ranks better than 85.9% on this metric.
During the past 12 months, Stoke Therapeutics's average EBITDA Per Share Growth Rate was -629.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 50.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 22.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Stoke Therapeutics was 50.60% per year. The lowest was -63.10% per year. And the median was -14.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Stoke Therapeutics 3-Year EBITDA Growth Rate Related Terms
STOK vs TYRA, SNDX, FTRE: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Stoke Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 50.60% mean?
Stoke Therapeutics (STOK) has a 3-Year EBITDA Growth Rate of 50.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Stoke Therapeutics and its competitors. According to the industry distribution chart, Stoke Therapeutics ranks #160 out of 1135 companies in the Biotechnology industry, placing it in the top 14.1%.
Is Stoke Therapeutics' 3-Year EBITDA Growth Rate too high?
Stoke Therapeutics' current 3-Year EBITDA Growth Rate is 50.60%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.80. Stoke Therapeutics' value of 50.60% is 241.9% above this industry median. Based on the distribution chart, Stoke Therapeutics ranks #160 out of 1135 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' 3-Year EBITDA Growth Rate compare to TYRA and SNDX?
According to the Biotechnology industry distribution chart, Stoke Therapeutics ranks #160 out of 1135 companies for 3-Year EBITDA Growth Rate. This places Stoke Therapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.80. Stoke Therapeutics' value of 50.60% is 241.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.80, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stoke Therapeutics's current 3-Year EBITDA Growth Rate of 50.60% is 241.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Stoke Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stoke Therapeutics's current 3-Year EBITDA Growth Rate is 50.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.45, compared to a current price of $32.20 — trading 240.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 50.60% and 241.9% above the Biotechnology industry median of 14.80. Stoke Therapeutics' overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current 3-Year EBITDA Growth Rate is 50.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stoke Therapeutics (STOK) Overvalued in 2026?
Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued.
The current stock price of $32.20 is trading 240.7% above its estimated GF Value™ of $9.45.
GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.
Key valuation signals for STOK:
3-Year EBITDA Growth Rate: 50.60%
GF Value™: $9.45 vs. price of $32.20 (240.7% above fair value)
Industry Position: 241.9% above the Biotechnology median (#160 of 1135)
No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score
Get the complete analysis for STOK
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STOK has been successfully added to your 
